Gritstone Raises $102m To Climb Cancer Vaccine Mountain
This article was originally published in Scrip
Just as rock climbers use gritstones to scale massive peaks, the San Francisco-based startup Gritstone Oncology raised $102m for the development of neoantigen-containing cancer vaccines that may help the immune system mount a targeted attack against tumors.
You may also be interested in...
Advaxis is developing – now with help from partner Amgen – a personalized immunotherapy strategy with each patient's cancer vaccine based on their own tumor's specific neoepitopes.
A report released May 19 from the industry organization confirms that oncology is attracting the most funding, while some other surprising therapeutics areas have become of interest to investors.
CAR-T therapy-associated T-cell malignancies that the US FDA is investigating could make the treatments less attractive in autoimmune diseases than in oncology, but patients in both settings already accept some cancer risk with other available medicines.